STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
SUTRO BIOPHARMA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.26+0.32 (+2.88%)
Close on Oct 19, 2026
- Market cap
- $186.51M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.16 (+11.44%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
SUTRO BIOPHARMA, INC. saw revenue fall 56.3% to $45.70M over the twelve months to Jun 30, 2026.
Revenue
$45.70M
-56.3% vs. a year earlier
Operating income
-$146.05M
TTM Q2 2026
EPS, diluted
-$17.32
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $186.51M
- P/E ratio
- –
- Price to sales
- 4.08
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $45.70M
- Net income
- -$180.64M
- EPS, diluted
- -$17.32
- Book value per share
- -$6.23
- Diluted shares
- 17M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$45.70M-56.3% YoY
Operating income
-$146.05M
Net income
-$180.64M
EPS, diluted
-$17.32
Free cash flow
–
Reported periodTrailing twelve months